Announcements on Extended Partnerships and Results of Clinical Trials - Research Report on Allscripts, Edwards Lifesciences,

   Announcements on Extended Partnerships and Results of Clinical Trials -
Research Report on Allscripts, Edwards Lifesciences, Varian, OPKO, and Globus
                                   Medical

Editor Note: For more information about this release, please scroll to bottom

PR Newswire

NEW YORK, June 20, 2013

NEW YORK, June 20, 2013 /PRNewswire/ --

Today, Wall Street Reports announced new research reports highlighting
Allscripts Healthcare Solutions, Inc. (NASDAQ: MDRX), Edwards Lifesciences
Corporation (NYSE: EW), Varian Medical Systems, Inc. (NYSE: VAR), OPKO Health,
Inc. (NYSE: OPK), and Globus Medical, Inc. (NYSE: GMED). Today's readers may
access these reports free of charge - including full price targets, industry
analysis and analyst ratings - via the links below.

Allscripts Healthcare Solutions,Inc. Research Report

On June 13, 2013, Allscripts Healthcare Solutions, Inc. (Allscripts) announced
that OnePartner Health Information Exchange (HIE) has extended its partnership
with the Company, adding the dbMotion platform to support HIE's growth.
Acquired by Allscripts in March 2013, dbMotion's capabilities will enhance the
ability of healthcare providers who participate in HIE to communicate with one
another to manage population health and enhance patient care. Further, the
partnership will help in a smooth transition for providers as the industry
moves from fee-for-service to fee-for-value. "Allscripts solutions are
enhancing multiple aspects of electronic connectivity in healthcare," said
Paul M. Black, President and CEO of Allscripts. The Full Research Report on
Allscripts Healthcare Solutions, Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.wsreports.com/r/full_research_report/1d85_MDRX]

--

Edwards Lifesciences Corporation Research Report

On June 17, 2013, Edwards Lifesciences Corporation (Edwards Lifesciences)
announced unprecedented long-term durability results for bovine pericardial
heart valves. The results are based on a study of the Carpentier-Edwards
PERIMOUNT aortic valve in a subset of patients aged 60 years or younger at the
time of operation. The study tracked patients for an almost 25-year period and
determined that expected valve durability for the patients was greater than 17
years. "Pericardial valve use has increased over time. These long-term data on
the PERIMOUNT valve strengthen the evidence for surgeons to utilize Edwards'
pericardial tissue valves, including in selected patients of age 60 and
under," said Prof. Michel Aupart, M.D., Head of the Department of
Cardiovascular and Thoracic Surgery, University Hospital of Tours, France, and
a consultant to Edwards Lifesciences. The Full Research Report on Edwards
Lifesciences Corporation - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at:
[http://www.wsreports.com/r/full_research_report/4fbc_EW]

--

Varian Medical Systems,Inc. Research Report

On June 13, 2013, Varian Medical Systems, Inc. (Varian) announced that
clinicians at The Ohio State University are now using Varian software to plan
and manage radiotherapy treatments delivered on a Siemens medical linear
accelerator. The Companies developed and deployed an interface that connects
Varian's ARIA oncology information system with Siemens' ONCOR and PRIMUS
accelerators and imaging systems. Siemens received 510(k) clearance in March
2013 from the US Food and Drug Administration (FDA) for connectivity between
Varian's ARIA software and Siemens' ONCOR and PRIMUS linear accelerators.
Further, Varian also launched a special service and support program to support
oncology treatment centers converting to ARIA from other third-party oncology
information systems. The Full Research Report on Varian Medical Systems, Inc.
- including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.wsreports.com/r/full_research_report/b046_VAR]

--

OPKO Health,Inc. Research Report

On May 23, 2013, OPKO Health, Inc. (OPKO) reported that the Company has
surpassed 50% enrollment in the first Phase 3 trial of Rayaldy to treat
patients with secondary hyperparathyroidism (SHPT), stage 3 or 4 chronic
kidney disease (CKD), and vitamin D insufficiency. The first trial is part of
two identical randomized, double-blind, placebo-controlled, multi-side
studies, which are designed to establish the safety and efficacy of Rayaldy as
a new treatment for SHPT in the targeted population. "Rayaldy is being
developed as a much needed and safer alternative to currently used activated
vitamin D hormones," said Dr. David Bushinsky, Chief of Nephrology at the
University of Rochester. Joel Z. Melnick, M.D., Vice President of Clinical
Research and Development at OPKO's Renal Division, added, "Most CKD patients
have insufficient stores of vitamin D due to the abnormal upregulation of
CYP24, an enzyme which specifically destroys vitamin D and its metabolites.
Many recent studies in CKD patients have demonstrated that over-the-counter
and presently available prescription vitamin D supplements cannot reliably
raise blood vitamin D prohormone levels or effectively treat SHPT. In
contrast, our phase 2b trial has demonstrated that Rayaldy effectively and
safely treats both SHPT and the underlying vitamin D insufficiency." The Full
Research Report on OPKO Health, Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.wsreports.com/r/full_research_report/cb42_OPK]

--

Globus Medical,Inc. Research Report

On June 17, 2013, Globus Medical, Inc. (Globus) announced jury verdict in a
patent infringement case in a US District Court brought by DePuy Synthes
Products, LLC (Synthes). Globus stated that a formal judgment has not yet been
entered in the case and there are a number of motions and hearings to be
resolved; however, the jury found that prior versions of three products
previously sold by Globus did infringe on Synthes' patents and awarded
monetary damages of $16 million. Globus does not expect this verdict to impact
its business or future revenues, as the said three products are no longer part
of the Company's product portfolio. Further, the Company does not expect the
verdict to impair Globus' ability to sell any of its current products and will
not require it to make any royalty payments to Synthes based on current or
future sales. However, the Company plans to overturn the verdict in post-trial
motions as it believes that the facts and the law do not support the jury's
findings of infringement and patent validity. The Full Research Report on
Globus Medical, Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.wsreports.com/r/full_research_report/5f95_GMED]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by a CFA. However, we are only human and are prone to
    make mistakes. If you notice any errors or omissions, please notify us
    below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquires, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

SOURCE Wall Street Reports

Contact: WSReports.com Phone #: +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.